Protagonist Therapeutics (PTGX) EBT Margin (2017 - 2026)
Protagonist Therapeutics (PTGX) posted EBT Margin of 4.05% for Q1 2026, up 100.69% sequentially from 587.84% in Q4 2025, and up 4520.0% YoY from 0.09% in Q1 2025.
Powered by 
Analysis
Protagonist Therapeutics (PTGX) EBT Margin (2017 - 2026) Analysis & Trends
Protagonist Therapeutics has reported EBT Margin for 10 years, with the latest figure at 4.05% in Q1 2026.
- Quarterly EBT Margin rose 4520.0% year-over-year to 4.05% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 155.78% (down 18400.0% YoY) and the FY2025 annual result came in at 281.01%, down 34532.0% from the prior year.
- EBT Margin advanced to 4.05% in Q1 2026 per PTGX's latest filing, from 587.84% in the prior quarter.
- Over five years, EBT Margin peaked at 82.63% in Q1 2024 and troughed at 4966.12% in Q2 2022.
- A 5-year average of 713.51% and a median of 424.05% in 2022 frame the typical range for EBT Margin.
- The widest YoY moves for EBT Margin: up 12750 bps in 2022, down 360445 bps in 2022.
- Over 5 years, EBT Margin stood at 4966.12% in 2022, then surged by 101 bps to 54.67% in 2023, then jumped by 48 bps to 80.99% in 2024, then slumped by 826 bps to 587.84% in 2025, then soared by 101 bps to 4.05% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 4.05%, 587.84%, and 834.87% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Protagonist Therapeutics | 9.61 Bn | 9.61 Bn | - | 77.35% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 77.35% |
| Mar 31, 2026 | 4.05% |
| Dec 31, 2025 | -594.24% |
| Sep 30, 2025 | -834.87% |
| Jun 30, 2025 | -623.86% |
| Mar 31, 2025 | -41.15% |
| Dec 31, 2024 | 81.01% |
| Sep 30, 2024 | -719.36% |
| Jun 30, 2024 | -750.95% |
| Mar 31, 2024 | 82.63% |
| Dec 31, 2023 | 54.67% |
| Dec 31, 2022 | 180,342.11% |
| Jun 30, 2022 | -4,551.00% |
| Mar 31, 2022 | -81.42% |
| Dec 31, 2021 | -431.16% |
| Sep 30, 2021 | -328.64% |
| Jun 30, 2021 | -1,361.68% |
| Mar 31, 2021 | -387.75% |
| Dec 31, 2020 | -444.50% |
| Sep 30, 2020 | -59.20% |